Full text
| |
| Author(s): |
Haroldo Alfredo Flores Toque
Total Authors: 1
|
| Document type: | Doctoral Thesis |
| Press: | Campinas, SP. |
| Institution: | Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Médicas |
| Defense date: | 2008-08-13 |
| Examining board members: |
Gilberto De Nucci;
Andre Sampaio Pupo;
Jose Eduardo Tanus Santos;
Kleber Gomes Franchini;
Stephen Hyslop
|
| Advisor: | Gilberto De Nucci |
| Abstract | |
Sildenafil, a cGMP-specific phosphodiesterase-5 (PDE5) inhibitor, is used for the treatment of erectile dysfunction. In the search for a potent and selective PDE5 inhibitor, new sildenafil analogues (6a-v), characterized by the presence on the sulphonyl group in the 5' position of novel N-4-substituted piperazines or ethylenediamine moiety, were synthesized. The aim of this work was 1) To evaluate the PDE5 inhibitory activity in human platelets; 2) To evaluate the relaxing effect of sildenafil analogues in rabbit corpus cavernosum; 3) To evaluate the relaxing effect of sildenafil analogues in rabbit isolated aorta. Blood from human volunteers were collected and used for PDE5 inhibitory activity and Male New Zealand rabbit (2-3 kg) for functional studies. The rabbits were anaesthetized with urethane and sacrificed. The cavernosal tissue and aortic rings were mounted in organ bath containing Krebs solution (37oC, 95% O2 / 5% CO2). Each tissue was connected to an isometric transducer which was connected to a data acquisition system Powerlab®. Our results showed that sildenafil and its analogues concentration-dependently inhibited PDE5 activity in human platelets. Compounds 6m, 6n and 6q showed higher values of IC50 to inhibit PDE5 of platelets, whereas compounds 6a, 6b, 6d, 6g and 6p did not reach 50% of inhibition. The inhibitory potency of PDE5 for 6c, 6e, 6f, 6h, 6i, 6l and 6o were similar with sildenafil (IC50: 0,05 µM) with values between 0,05-0,15 µM. Derived analogues from n'n' substitution showed great PDE5 inhibitory activity. Interesting, compound 6u exhibited greater IC50 value (0,04 µM). In functional studies, all sildenafil analogues with exception of 6m, relaxed concentration-dependently rabbit corpus cavernosum. Compound 6f exhibited great pEC50 value in corpus cavernosum and could be used as base for developing new PDE5 inhibitors. Moreover, our results showed that sildenafil analogues concentration-dependently relaxed both endothelium-intact and - denuded aortic rings with similar potency values of sildenafil. Compounds 6b and 6m showed lower values of potency when compared to sildenafil in endothelium intact. Endothelium denudation or addition of L-NAME or ODQ (NOS and sGC inhibitors, respectively) caused marked rightward shifts in the curve to sildenafil and its analogues, whereas the relaxation curves for 6r and 6u were not altered after endothelium removal or either by the NO synthase or sGC inhibition. Moreover, our data also suggest that compound 6r and 6u increased the potency values in combination with BAY 41-2272 in both intact and denuded endothelium. The relaxation evoked by sildenafil, 6r and 6u does not involve either calcium or potassium channels or prostanoids formation. The relaxing responses by these compounds were independent of NO/cGMP pathway, suggesting that these compounds may be used in several diseases involving endothelium dysfunction. (AU) | |